ALLO – allogene therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
Allogene Therapeutics, Inc. (NASDAQ: ALLO) was upgraded by analysts at Citizens Jmp from a "market perform" rating to an "outperform" rating. They now have a $5.00 price target on the stock.
Form 4 Allogene Therapeutics, For: Mar 14 Filed by: Chang David D
Form 4 Allogene Therapeutics, For: Mar 14 Filed by: Beneski Benjamin Machinas
Form 144 Allogene Therapeutics, Filed by: Beneski Benjamin Machinas
Form 144 Allogene Therapeutics, Filed by: Chang David D
Form S-8 Allogene Therapeutics,
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.